Fresenius Kabi’s Tyenne (biosimilar, tocilizumab) Receives EC’s Approval for Multiple Inflammatory and Immune Mediated Conditions
Shots:
- The EC has granted marketing authorization for tocilizumab biosimilar Tyenne to treat multiple inflammatory & immune-mediated conditions, incl. RA, giant cell arteritis, polyarticular JIA, and systemic juvenile idiopathic arthritis, CRS as well as for COVID-19
- The company also received EC approval for both SC (prefilled syringe and autoinjector) & IV formulations which provide comprehensive, alternative treatment solutions for healthcare professionals & patients
- Fresenius Kabi’s Tyenne, the third approved biosimilar in the EU expanding its biosimilar portfolio focused on autoimmune diseases & oncology. The company offers a comprehensive patient support program KabiCare which will be available to patients & healthcare providers from its launch in the EU
Ref: Fresenius | Image: Fresenius
Related News:- Fresenius Kabi Reports the Commercial Availability of Plerixafor Injection
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
